Validation of Novel Prognostic Biomarkers for Early-Stage Clear-Cell, Endometrioid and Mucinous Ovarian Carcinomas Using Immunohistochemistry
Early-stage (I and II) ovarian carcinoma patients generally have good prognosis. Yet, some patients die earlier than expected. Thus, it is important to stratify early-stage patients into risk groups to identify those in need of more aggressive treatment regimens. The prognostic value of 29 histotype...
Main Authors: | Hanna Engqvist, Toshima Z. Parris, Anikó Kovács, Elisabeth Werner Rönnerman, Karin Sundfeldt, Per Karlsson, Khalil Helou |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-02-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2020.00162/full |
Similar Items
-
Trefoil factor family proteins as potential diagnostic markers for mucinous invasive ovarian carcinoma
by: Elisabeth Werner Rönnerman, et al.
Published: (2023-02-01) -
Ovarian endometrioid carcinoma and clear cell carcinoma: A 21-year retrospective study
by: Ling Zhou, et al.
Published: (2021-05-01) -
Immunohistochemical validation of COL3A1, GPR158 and PITHD1 as prognostic biomarkers in early-stage ovarian carcinomas
by: Hanna Engqvist, et al.
Published: (2019-09-01) -
Ovarian Endometrioid and Clear Cell Carcinomas with Low Prevalence of Microsatellite Instability: A Unique Subset of Ovarian Carcinomas Could Benefit from Combination Therapy with Immune Checkpoint Inhibitors and Other Anticancer Agents
by: Yuki Nonomura, et al.
Published: (2022-04-01) -
Ovarian carcinoma histotype in Lynch syndrome
by: C. Blake Gilks, et al.
Published: (2017-05-01)